Zw. Sun et al., Beneficial effects of lexipafant, a PAF antagonist on gut barrier dysfunction caused by intestinal ischemia and reperfusion in rats, DIGEST SURG, 17(1), 2000, pp. 57-65
Background: Platelet-activating factor (PAF) may play a pivotal role in the
pathogenesis of intestinal ischemic injury. Methods: The potential role of
PAF in intestinal ischemia and reperfusion (I/R) and the development of gu
t endothelial and epithelial barrier dysfunction and distant organ injury w
ere investigated by pretreatment with a PAF antagonist, lexipafant. Bidirec
tional permeability of the intestinal barrier, enteric bacterial translocat
ion, protease-antiprotease balance and mucosal histology, and also changes
in pulmonary and liver endothelial barrier permeability were measured follo
wing intestinal ischemia for 40 min with 6 h of reperfusion in rats. Result
s: Intestinal mucosal endothelial and epithelial permeabilities significant
ly increased in animals with I/R. Lexipafant prevented the increase in albu
min leakage from blood to the mucosal interstitium and the intestinal lumen
during reperfusion, and the mucosal albumin leakage from the gut lumen to
blood during I/R. Bacterial translocation was frequently noted in animals w
ith I/R, while only a few positive cultures were obtained in animals with I
/R administered lexipafant. Less leakage of fluorescein isothiocyanate dext
ran 70,000 into the interstitial space and gut lumen in I/R animals with le
xipafant pretreatment was found under fluorescein microscopy. Lexipafant al
so partly prevented C1 inhibitor, prekallikrein, and factor X consumption i
n I/R animals and partly prevented changes in pulmonary and liver albumin l
eakage. Conclusions: PAF seems to play an important role in I/R-associated
intestinal dysfunction and the development of distant organ dysfunction, pr
obably by triggering endothelial and epithelial barrier dysfunction. furthe
rmore, PAF seems to be partly involved in activation of the protease-a nti
protease system. The use of PAF antagonists may provide a mode of treatment
against I/R-associated organ dysfunction. Copyright (C) 2000 S. Karser AG,
Basel.